

**EFFICACY AND SAFETY OF COADMINISTERED AMIODARONE AND TRIMETAZIDINE IN PATIENTS WITH LIFE-THREATENING ARRHYTHMIAS**

Sh. Chumburidze, G.Shelia

National Center of therapy, Tbilisi, Georgia

**AIM :** To assess the efficacy and safety of co-administered amiodarone (A) and trimetazidine (T) in patients with coronary artery disease (CAD) and life-threatening ventricular arrhythmias (Ar).

**METHODS.** We studied 30 pts (20 men, 10 women, mean age  $45.9\pm 4.7$  years) with CAD and life-threatening ventricular Ar (Lawn class III or higher). Echocardiography, 24-hour ECG monitoring, and assessment of quality of life were performed. Patients were divided into the groups. The first group (n=10) received A (400 to 600 mg), the second group (n=10) T (35mg), and the third group (n=10) A+T.

Background therapy was similar for all groups and consisted of long-acting nitrates, ACE inhibitors, statins and aspirin. Duration of the study was 1 month.

**RESULTS.** At the end of the study, there were significant and sustained improvements in LV systolic and diastolic function in all groups, but changes were more important in A+T group.

The 24-h ECG monitoring revealed more significant reduction of extra-systolic episodes in the A+T group (86%) compared with the A and T groups. Improvement of quality of life was also more significant in the A+T group.

Therapy with A+T was well tolerated, with no serious adverse events observed in any of the patients.

**CONCLUSIONS.** Thus, we conclude that A+T combination is an effective treatment for patients with CAD and life-threatening ventricular Ar.

**Keyword:** Life-threatening ventricular arrhythmia, Amiodarone, Trimetazidine